SCHEMBL4721790

SCHEMBL4721790

CCCN(C)c1cccc2c1[CH]c1ccccc1-2

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DRD3 P35462 3/20 0.35
HTR1A P08908 2/20 0.34
DRD2 P14416 2/20 0.34
HTR2A P28223 2/20 0.34
SLC6A4 P31645 2/20 0.34
HRH1 P35367 2/20 0.34
TP53 P04637 1/20 0.34
CYP1A2 P05177 1/20 0.34
RET P07949 1/20 0.34
CHRM2 P08172 1/20 0.34
CYP2D6 P10635 1/20 0.34
CHRM1 P11229 1/20 0.34
ALOX15 P16050 1/20 0.34
TSHR P16473 1/20 0.34
ADRA2C P18825 1/20 0.34
CHRM3 P20309 1/20 0.34
SLC6A2 P23975 1/20 0.34
HTR2C P28335 1/20 0.34
ADRA1A P35348 1/20 0.34
THPO P40225 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4723422 0.91 KDM4E (0.40) DRD3HTR1ADRD2HTR2ASLC6A4
SCHEMBL4719924 0.87 TP53 (0.33) DRD3HTR1ADRD2HTR2ASLC6A4
SCHEMBL4765912 0.85 CRHR1 (0.40) DRD3HTR1ADRD2HTR2ASLC6A4
SCHEMBL4723530 0.83 CRHR1 (0.35) DRD3HTR1ADRD2HTR2ASLC6A4
SCHEMBL4724521 0.80 CRHR1 (0.40) DRD3LMNAMEN1KMT2ACRHR1
SCHEMBL4724339 0.79 CRHR1 (0.36) DRD3TP53LMNAMEN1KMT2A
SCHEMBL215956 0.79 MAPT (0.43) DRD3HTR1ADRD2HTR2ASLC6A4
SCHEMBL4722979 0.78 MEN1 (0.36) DRD3HTR1ADRD2HTR2ASLC6A4
SCHEMBL4721732 0.77 CRHR1 (0.39) TSHRLMNAMEN1KMT2ACRHR1
SCHEMBL15400228 0.73 KDM4E (0.32) CYP1A2CYP2D6ALDH1A1MAPTTDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080176857-A1 4-Piperazinnylthieno[2,3-d]Pyrimidine Compounds as Platelet Aggregation Inhibitors PFIZER INC. 2008-07-24 US disclosed
EP-1874780-A1 4-PIPERAZINYLTHIENO[2,3-D]PYRIMIDINE COMPOUNDS AS PLATELET AGGREGATION INHIBITORS Pharmacia & Upjohn Company LLC (US) 2008-01-09 EP disclosed
WO-2006100591-A1 4-PIPERAZINNYLTHIENO [2,3-D] PYRIMIDINE COMPOUNDS AS PLATELET AGGREGATION INHIBITORS PHARMACIA & UPJOHN COMPANY LLC (US) 2006-09-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080176857-A1 4-Piperazinnylthieno[2,3-d]Pyrimidine Compounds as Platelet Aggregation Inhibitors TBXA2R, P2RY4, PF4 DRD3 509/4885HTR1A 93/4885DRD2 539/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.